TG

Tassos Gianakakos

CEO at MyoKardia

Tassos Gianakakos is the current CEO at MyoKardia. Prior to this, they were the SVP, Chief Business Officer at MAP Pharmaceuticals from September 2006 to March 2013. Tassos has also served as the SVP Business Development and President Pharmaceuticals at Codexis from January 2002 to December 2006, and as the Director of Business Development at Maxygen from January 1998 to December 2002. Tassos Gianakakos began their career as a Process Engineer at Merck from January 1995 to December 1997.

Tassos Gianakakos received a BS in Chemical Engineering from the Massachusetts Institute of Technology and a BS in Economics from the same school. Tassos then went on to receive an MBA from Harvard Business School. Finally, they received a MS in Biotechnology from Northwestern University.

Joseph Lambing - SVP, Nonclinical and Pharmaceutical Development, Holly Schachner - SVP, Therapeutic Area, and Robert S. Mcdowell - Chief Scientific Officer report to Tassos Gianakakos.

Links

Timeline

  • CEO

    Current role

View in org chart